tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ACRV Stock Latest News

Acrivon Therapeutics Reports Q2 2025 Financial Results
Company AnnouncementsAcrivon Therapeutics Reports Q2 2025 Financial Results
1h ago
ACRV
Acrivon Therapeutics reports Q2 EPS (55c), consensus (58c)
PremiumThe Fly
Acrivon Therapeutics reports Q2 EPS (55c), consensus (58c)
9h ago
ACRV
Acrivon Therapeutics Holds Annual Stockholders Meeting
PremiumCompany Announcements
Acrivon Therapeutics Holds Annual Stockholders Meeting
2M ago
8K
ACRV
Acrivon Therapeutics: Promising Clinical Developments and Strategic Focus Support Buy Rating
PremiumRatings
Acrivon Therapeutics: Promising Clinical Developments and Strategic Focus Support Buy Rating
3M ago
ACRV
Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch
PremiumThe Fly
Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch
3M ago
ACRV
Acrivon Therapeutics, Inc.: Promising Clinical Data and Strategic Advancements Justify Buy Rating
PremiumRatingsAcrivon Therapeutics, Inc.: Promising Clinical Data and Strategic Advancements Justify Buy Rating
3M ago
ACRV
Acrivon Therapeutics Reports Q1 2025 Progress and Financials
Premium
Company Announcements
Acrivon Therapeutics Reports Q1 2025 Progress and Financials
3M ago
ACRV
Acrivon Therapeutics price target lowered to $9 from $10 at Oppenheimer
Premium
The Fly
Acrivon Therapeutics price target lowered to $9 from $10 at Oppenheimer
3M ago
ACRV
Optimistic Outlook for Acrivon Therapeutics: Promising ACR-368 Results and Strategic Focus on Endometrial Cancer
PremiumRatings
Optimistic Outlook for Acrivon Therapeutics: Promising ACR-368 Results and Strategic Focus on Endometrial Cancer
3M ago
ACRV
Acrivon Therapeutics reports Q1 EPS (51c), consensus (65c)
PremiumThe Fly
Acrivon Therapeutics reports Q1 EPS (51c), consensus (65c)
3M ago
ACRV
Acrivon Therapeutics sees cash, equivalents funding expenses into 2Q27
PremiumThe Fly
Acrivon Therapeutics sees cash, equivalents funding expenses into 2Q27
3M ago
ACRV
Acrivon Therapeutics assumed with an Overweight at Piper Sandler
PremiumThe Fly
Acrivon Therapeutics assumed with an Overweight at Piper Sandler
3M ago
ACRV
Biotech Alert: Searches spiking for these stocks today
PremiumThe FlyBiotech Alert: Searches spiking for these stocks today
4M ago
ACRV
AZTR
Acrivon Therapeutics to present data from analyses of ACR-2316 at AACR
Premium
The Fly
Acrivon Therapeutics to present data from analyses of ACR-2316 at AACR
4M ago
ACRV
Biotech Alert: Searches spiking for these stocks today
Premium
The Fly
Biotech Alert: Searches spiking for these stocks today
4M ago
NBY
PTN
Acrivon Therapeutics Reports Progress in Cancer Drug Development
PremiumCompany Announcements
Acrivon Therapeutics Reports Progress in Cancer Drug Development
4M ago
ACRV
Acrivon Therapeutics Appoints New Chief Medical Officer
PremiumCompany Announcements
Acrivon Therapeutics Appoints New Chief Medical Officer
4M ago
8K
ACRV
Acrivon appoints Mansoor Raza Mirza as Chief Medical Officer
PremiumThe Fly
Acrivon appoints Mansoor Raza Mirza as Chief Medical Officer
4M ago
ACRV
Buy Rating Reaffirmed for Acrivon Therapeutics Amid Promising Endometrial Cancer Data and Strong Financial Position
PremiumRatings
Buy Rating Reaffirmed for Acrivon Therapeutics Amid Promising Endometrial Cancer Data and Strong Financial Position
4M ago
ACRV
Acrivon Therapeutics price target lowered to $7 from $22 at JonesResearch
PremiumThe FlyAcrivon Therapeutics price target lowered to $7 from $22 at JonesResearch
4M ago
ACRV
Acrivon Therapeutics price target lowered to $10 from $18 at Oppenheimer
Premium
The Fly
Acrivon Therapeutics price target lowered to $10 from $18 at Oppenheimer
5M ago
ACRV
Acrivon Therapeutics reports Q4 EPS (60c), consensus (70c)
Premium
The Fly
Acrivon Therapeutics reports Q4 EPS (60c), consensus (70c)
5M ago
ACRV

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >